Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose cyclophosphamide vs DLI to prevent relapse after haploidentical SCT in high-risk acute leukemia
IRCT201208041030N11Phase 3Completed
- Sponsor
- Hematology, Oncology and Stem Cell Transplantation Research Center
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cyclophosphamide in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Hematology, Oncology and Stem Cell Transplantation Research Center. Started Nov 2009; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on IRCT201208041030N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201208041030N11.